financetom
Business
financetom
/
Business
/
DuPont de Nemours Lowers Q3, Full-Year Sales Outlook to Reflect Spin-Off
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
DuPont de Nemours Lowers Q3, Full-Year Sales Outlook to Reflect Spin-Off
Sep 18, 2025 5:13 AM

07:53 AM EDT, 09/18/2025 (MT Newswires) -- DuPont de Nemours ( DD ) Thursday said it expects Q3 adjusted earnings of $1.06 per share on net sales of about $2.98 billion, compared with August estimate of Q3 adjusted EPS of $1.15 on net sales of $3.32 billion.

Analysts polled by FactSet expect non-GAAP EPS of $1.16 on sales of $3.31 billion, which may not be comparable.

For full-year 2025, the company said it will provide its full-year adjusted EPS outlook at the third quarter 2025 earnings call as it is finalizing its capital structure. DuPont ( DD ) expects full-year 2025 net sales of $6.87 billion. Analysts surveyed by FactSet expect $12.84 billion, which may not be comparable. In August, the company estimated full-year 2025 adjusted EPS of $4.40 on net sales of $12.85 billion.

The company said its 2025 guidance reflects the Aramids divestiture and the planned Nov. 1 separation of its Qnity Electronics unit, which will be reported as discontinued operations starting in Q3 and Q4, respectively.

DuPont ( DD ) said its medium-term targets through 2028 include 3% to 4% organic sales growth compound annual growth rate, or CAGR and 8% to 10% adjusted EPS growth CAGR, excluding deployment of excess free cash flow.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US CDC vaccine panel postpones vote on RSV therapies
US CDC vaccine panel postpones vote on RSV therapies
Jun 25, 2025
June 25 (Reuters) - The U.S. Centers for Disease Control and Prevention's revamped vaccine advisory panel on Wednesday postponed its vote on the use of respiratory syncytial virus therapies to Thursday. The panel, which has convened for a closely watched two-day meeting, was discussing the use of AstraZeneca ( AZN ) and Sanofi's Beyfortus and Merck's ( MRK ) Enflonsia....
Kymera Therapeutics Commences $250 Million Public Offering
Kymera Therapeutics Commences $250 Million Public Offering
Jun 25, 2025
04:35 PM EDT, 06/25/2025 (MT Newswires) -- Kymera Therapeutics ( KYMR ) shares fell over 5% during after-hours trading on Wednesday after the company said it commenced a public offering of $250 million of common shares and pre-funded warrants. The company plans to offer underwriters a 30-day overallotment option to buy up to an additional $37.5 million common shares at...
Steelcase Posts Higher Fiscal Q1 Results; Sets Q2 Outlook
Steelcase Posts Higher Fiscal Q1 Results; Sets Q2 Outlook
Jun 25, 2025
04:36 PM EDT, 06/25/2025 (MT Newswires) -- Steelcase ( SCS ) reported late Wednesday fiscal Q1 adjusted earnings of $0.20 per diluted share, up from $0.16 a year ago. Analysts polled by FactSet expected $0.14. Revenue for the quarter ended May 30 was $779.0 million, up from $727.3 million a year earlier. Analysts surveyed by FactSet expected $762.4 million. For...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved